Informations générales (source: ClinicalTrials.gov)
Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC) (ICONIC)
Interventional
N/A
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
août 2020
février 2026
05 avril 2025
Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public
health issue with very high direct and indirect costs. The impact on the health system of
undiagnosed patients, up to 70% of patients, is increasingly documented. However,
systematic spirometry screening remains controversial among smokers in the absence of
data to link the detection of new patients with improved management and clinical events
and health goals. More generally, there is little data on the evolution of patients in
real life once they have entered the care system.
The premise is that with systematic screening in general medicine, it is possible to
identify the evolution of newly diagnosed COPD patients, to distinguish the different
possible evolutions according to the initial phenotype and the management.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Bernard MAITRE | 06/02/2025 16:27:06 | Contacter | ||
Critères
Tous
Inclusion Criteria:
Inclusion criteria of smokers with spirometry (pre-inclusion)
- Age> 35 years
- Smoking > 20 PA
- Active smoking (cessation < 1 month)
- Signature of consent to participate in Phase I of the study
Inclusion criteria for patients with incidental COPD
- FEV1 / FVC <70% of the theoretical value and / or <LLN (Lower limit of normal)
- Signature of consent to participate in Phase II of the study
Inclusion criteria of smokers with spirometry (pre-inclusion)
- Age> 35 years
- Smoking > 20 PA
- Active smoking (cessation < 1 month)
- Signature of consent to participate in Phase I of the study
Inclusion criteria for patients with incidental COPD
- FEV1 / FVC <70% of the theoretical value and / or <LLN (Lower limit of normal)
- Signature of consent to participate in Phase II of the study
- Known COPD
- Cancer being treated
- No affiliation to the social security or other social protection scheme
- Pregnant or lactating woman
- Patient deprived of liberty or under legal protection (under tutorship or
curatorship